GLP1R and atherosclerosis: Pre-clinical studies have shown a reduction of atherosclerosis formation by GLP-1 RAs through inhibition of plaque progression and promoting plague stabilization37; GLP-1 RAs may reduce systemic and vascular inflammation by lowering the expression of inflammatory proteins involved in the development and progression of atherosclerosis38; and finally, studies have suggested a dose-dependent effect between GLP-1 RAs and changes in BP by increasing electrolytes excretion39,40 and reducing the circulating levels of RAS system components.41